Think Ethnobridging Sooner!
Planning a Phase I clinical trial? Consider an ethnobridging strategy.
By conducting vital analyses on Asian participants during Phase I studies conducted in Western regions, you can significantly cut costs and shorten the NDA timeline. This strategy streamlines the approval process in Asian markets and addresses potential disparities in drug metabolism between Asian and non-Asian populations.
Here are some key resources for ethnobridging in Phase I clinical trials:
In this issue of The Altascientist, we demonstrate how ethnobridging can prevent the need for region-specific development programs, helping you safely achieve commercial milestones more efficiently.
In this complimentary webinar, Mel B. Affrime, PharmD, Executive Vice President, Translational Medicine, discusses how ethnic differences can impact the bioavailability of your drug candidate and how to design a multiregional clinical development program to hasten worldwide regulatory approval safely.
Speak with an expert today to discuss your next clinical program.
You may also be interested in the following webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.